Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia . The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A pharmaceutical composition comprising a purified bacterial mixture of at least two viable bacterial strains selected from the group consisting of Clostridium leptum, Clostridium clostridioforme, Clostridium indolis, Clostridium oroticum, Clostridium scindens, Clostridium sphenoides , and Clostridium symbiosum , wherein the bacterial strains are isolated from a human, wherein the pharmaceutical composition is formulated for delivery to the intestine, and wherein the pharmaceutical composition does not include at least one of Lactobacillus, Bifidobacterium , and Bacteroides.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include Lactobacillus.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include Bifidobacterium.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include Bacteroides.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include any of Lactobacillus, Bifidobacterium , or Bacteroides.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated as a capsule.
8. The pharmaceutical composition of claim 1 , wherein at least one of the viable bacterial strains is spore-forming.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is effective for treating inflammatory bowel disease.
10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least one of Clostridium indolis and Clostridium symbiosum.
11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises Clostridium indolis and Clostridium symbiosum.
12. A pharmaceutical composition comprising a purified bacterial mixture of at least two live bacterial strains selected from the group consisting of Clostridium indolis, Clostridium scindens, Clostridium symbiosum , and Blautia producta , wherein said pharmaceutical composition is formulated for delivery to the intestine, and wherein said pharmaceutical composition does not include at least one of Lactobacillus, Bifidobacterium , and Bacteroides.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises all of Clostridium indolis, Clostridium scindens, Clostridium symbiosum , and Blautia producta.
14. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises at least one of Clostridium indolis and Clostridium symbiosum.
15. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises Clostridium indolis and Clostridium symbiosum.
16. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition does not include Lactobacillus.
17. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition does not include Bifidobacterium.
18. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition does not include Bacteroides.
19. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition does not include any of Lactobacillus, Bifidobacterium , or Bacteroides.
20. The pharmaceutical composition of claim 12 , wherein at least one of the viable bacterial strains is spore-forming.